Labcorp and ConcertAI optimize precision oncology research with real-world data and artificial intelligence
Collaboration Aims to Increase Equitable Trial Access and Patient Retention
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005566/en/
Through this collaboration,
“With Labcorp, we are building an advanced network, AI technologies and SaaS solutions to further advance the industry’s goals for diversity and digital enablement in clinical development services, especially in oncology,” said
ConcertAI’s offerings will allow Labcorp Drug Development to access data to make more informed decisions about oncology clinical trials. This analytical toolset drives actionable insights that will lead to a better understanding of patient profiles and treatment pathways, ultimately yielding quicker and more effective clinical trials.
Clinical trials also increasingly require analysis of potential trial sites to identify and select locations containing patients with specific characteristics. Using data to help understand the availability of patients across a sampling of oncology cancer centers helps bring health care within reach for all and ensures that the design of a trial contains a diverse set of participants to measure drug safety and effectiveness in broadly representative populations. ConcertAI and
“Oncology is highly complex, with hundreds of molecular targets and factors across solid tumors and hematological malignancies, so the need is great for diversity in cancer trials,” said
Improved screening, along with new diagnostics and treatments in cancer have been significant contributors to recent reductions in deaths and other adverse outcomes. Health care providers and pharmaceutical companies require support to bring additional, innovative treatment options to market. Pairing ConcertAI’s RWD and AI expertise with Labcorp Drug Development’s established site relationships and patient-centric approach will provide customers with a differentiated offering, generating actionable insights and improved trial execution—ultimately yielding trials that are more cost effective, more inclusive and more likely to succeed.
About
About ConcertAI
ConcertAI is the leader in Real-World Evidence (RWE) and AI technology solutions for life sciences and health care. Our mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies. For more information, visit us at http://www.concertai.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005566/en/
Labcorp Contacts:
Media:
[email protected]
Investors:
[email protected]
ConcertAI Contacts:
Marketing:
[email protected]
Source: